Pipeline Conference 2020 - Epilepsy Foundation

Santa Clara, California, March 12 – March 13, 2020

Solebury Trout will be sponsoring the 2020 Epilipsy Pipeline Conference. In order to register please click on the following link:



Conference Agenda

Times are pacific standard time (PST). Please note that the agenda will be continually updated as speakers confirm their slots.

Day 1 – Thursday, March 12, 2020

Registration And Breakfast – 7:00-8:00 A.M.

Welcome And Overview – 8:00-8:15 A.M.

  • Jacqueline French MD, Chief Medical and Innovation Officer, Epilepsy Foundation
  • Robert Smith, Interim CEO, Epilepsy Foundation
  • Kerry Youker, Board Chair, Epilepsy Foundation Northern California

Session I: We Know Where We've Been. Do We Know Where We Are Going? – 8:15-9:05 A.M.

  • Lecture: Past Successes – Sonya Dumanis PhD, Senior Director of Innovation, Epilepsy Foundation
  • Panel: Future Challenges  Daniel Fischer, Founder of Tevard Biosciences; Greg Mayes, CEO & Founder of Engage Therapeutics; Yssa DeWoody, President of Ring14 USA; Ilene Penn Miller, Rare Epilepsy Network

Session II: Diagnosis And Detection Devices – 9:05-11:35 A.M.

  • Lecture: Can SUDEP be avoided with devices?– Sam Lhatoo MD, FRCP, UT Health
  • Lecture: My Seizure Gauge, Seizure Forecasting, and the Future of Therapeutics – Dean Freestone PhD, Co-Founder, Seer Medical
  • 3D Optical Scanner and Machine Vision Platform, Advanced Scanners – Aaron Bernstein, CTO, Co-Founder & CEO
  • SPEAC System, Brain Sentinel – Luke Whitmire PhD, Chief Scientific Officer
  • SeizeIT, Byteflies & UCB – Benjamin Vandendriessche, CMO & Gergely Vertes, Seizure Freedom Mission Solution Accelerator
  • Embrace Platform and Device, Empatica – Matteo Lai, Co-Founder & CEO
  • Epihunter Tracker, Epihunter – Dirk Loeckx PhD, Chief Scientific Officer
  • Nelli Seizure Monitoring Tool, Go North Medical, Neuro Event Labs – Glen Fotland, Founder
  • Captureproof Platform, Captureproof  – Meghan Conroy, Founder & CEO
  • TMS-EEG, Kings College London – Isabella Premoli MD
  • UNEEG 24/7 SubQ, UNEEG Medical – Lykke Blaabjerg, Head of Clinical Affairs
  • Epi-Minder sub-scalp system, Epi-Minder – Mark Cook, Director of Neurology, Melbourne University
  • Epilog wearable device, Epitel – Mark Lehmkuhle PhD, CEO/CTO

Networking Break – 11:35-11:50 A.M.

Session III: Therapeutic Devices – 11:50 A.M.-12:20 P.M.

  • Cathodal Transcranial Direct Current Stimulation, tDCS, Neuroelectrics  –Alexander Rotenburg MD
  • DyNeuMo implantable device and platform, DyNeuMo – Timothy Denison PhD, Professor of Neurotechnlogy, University of Oxford
  • RNS System, NeuroPace – David King-Stephens MD, California Pacific Medical Center

Session IV: Investor Panel – 12:20-12:55 P.M.

Networking Lunch – 12:55-1:55 P.M.

Session V: What We Still Need In Drugs For Focal Epilepsy – 1:55-3:30 P.M. 

  • Lecture: What would make a new focal epilepsy drug successful in the marketplace? – Daniel Friedman MD, New York University Langone Medical Center
  • 2-Deoxy-d-Glucose (2DG), University of Wisconsin –Thomas Sutula MD, PhD
  • Inhibitory interneuron cell therapy, Neurona Therapeutics  Cory Nicholas PhD, CEO & Co-Founder
  • Adenosine kinase inhibitors, Robert Wood Johnson Medical School  Detlev Boison PhD
  • Revivo-5061, Revivo Therapeutics  Doug Cowart PharmD, CEO
  • Cenobamate and Carisbamate, SK Life Sciences  William Rosenfeld MD
  • XEN1101, Xenon Pharma  Ernesto Aycardi MD, Chief Medical Officer
  • NC201, NeuCyte  Hui Liu PhD, Director, Drug Discovery
  • Padsevonil, UCB  Konrad Werhahn MD, Senior Medical Director, Global Clinical Development

Networking Break – 3:30-4:00 P.M.

Update From 2019 Shark Tank Winners – 4:00-4:30 P.M.

  • Rachel Kuperman MD, CEO of Eysz, Inc.
  • Jody McNannay, Co-Founder, Curadite, Inc. and parent of a daughter with epilepsy

2020 Shark Tank Competition – 4:30-6:30 P.M.

  • Aditya Kadambi from Mocxa for their automated privacy enhancement for seizure videos
  • Atilla Borbath from Synergia Medical for their NAO-VNS product
  • Boris Goldstein PhD from Brain Scientific for his graphene electrodes in under the skin EEG implants
  • Jong Woo Lee MD along with Product Architectures for their night-time SUDEP prevention device
  • Keely McCarthy, parent of a child living with epilepsy, for her emergency epilepsy band

Accelerator Award Reception & Presentation – 6:30-8:30 P.M.

Day 2 – Friday, March 13, 2020

Day 2 Welcome – 8:00-8:15 A.M.

  • Kathleen Farrell MB BCh BAO, Senior Director of Clinical Research, Epilepsy Foundation 
  • Sylvia Olvera MD, Kaiser Permanente 

Session VI: Screening – 8:15-9:10 A.M.

  • Lecture: Status report on NINDS Translational Epilepsy Research – Brian Klein PhD, NINDS
  • Lecture: Screening Across the Board: Where are we and where should we be going? – Mike Rogawski MD, PhD, University California Davis
  • NeuCyte platform, NeuCyte – Thomas Portmann PhD, Associate Director, Head of Research
  • CUE Platform, SynapCell – Corinne Roucard PhD, CEO and Head of Business Development

Session VII: Genetics – 9:10-9:55 A.M.

  • Lecture: Mechanisms of intervention in single gene diseases – Annapurna Poduri MD, MPH, Boston Children’s Hospital
  • STK-001, Stoke Therapeutics​ – Barry Ticho MD, PhD, Chief Medical Officer
  • Atalurin, PTC Therapeutics – Quintus Ngumah, PhD, VP Clinical Development
  • EXT101, Encoded Therapeutics – Rosie O’Donnell MD, Senior Advisor, Clinical Development

Networking Break – 9:55-10:15 A.M.

Session VIII: Data-Driven Solutions – 10:15-11:50 A.M.

  • Lecture: What can we learn from aggregated data and why should we be capturing it? – David Voccola, Prometheus Research, Co-Founder
  • ​Epilepsy Data Experiential Network (EDEN) – Jacqueline French MD, Chief Medical Innovation Officer, Epilepsy Foundation
  • Epilepsy Learning Healthcare System – Brandy Fureman PhD, Vice President of Research and New Therapies, Epilepsy Foundation
  • Seer Platform, Seer Medical – Dean Freestone PhD, Co-Founder
  • Using AI to predict AED response, UCB – Martin Armstrong PhD, Head of Genetics
  • Doc.AI platform, Doc.AI – Sam De Brouwer PhD, Co-Founder
  • Predictor of AED Response through Advanced Data analysis of EEG (PARADE), Epilog – Gregor Strobbe PhD, Co-CEO
  • Epistemic app, Epistemic – Paula Gomez PhD, MBA, CEO and Co-founder
  • BioSerenity platform, BioSerenity – Bruce Lavin MD, MPH, Chief Medical Officer

Session IX: Rare And Ultra-Rare Diseases – 11:50 A.M.-12:20 P.M.

  • Lecture: Efficient trials and Ultra-Rare Diseases - An Overview of the 2019 Research Roundtable for Epilepsy – Dennis Dlugos MD, Children’s Hospital of Philadelphia
  • Lecture: Rare Populations Interactions with FDA
    • Steve Roberds PhD, Chief Scientific Officer Tuberous Sclerosis Alliance

Networking Lunch – 12:20-1:20 P.M.

Session IX Continued: Rare And Ultra-Rare Diseases – 1:20-3:20 P.M.

  • KB-3061, Knopp Biosciences – Steven Dworetzky PhD, Vice President of Discovery Research
  • Tak-935/OV935, Takeda Pharmaceuticals – Mahnaz Asgharnejad PharmD, Vice President of Clinical Development
  • UX-068, Ultragenyx – Melanie Brandabur MD, Medical Director
  • VAL-0417 and VAL-1221, Valerion Therapeutics – Matthew Gentry PhD
  • XEN-496,  Xenon Pharma – Ernesto Aycardi, Chief Medical Officer
  • ZX008, Zogenix​ – Glenn Morrison PhD, Vice President of Global Clinical Development
  • Anavex 2-73, Anavex Life Sciences​ – Walter Kaufmann MD, Chief Medical Officer
  • AE116, Aeovian Pharmaceuticals – Stelios Tzannis PhD, President & CEO
  • Natalizumab, Biogen – Kim Parkerson MD, PhD, Medical Director, Epilepsy and Neurodevelopment  
  • PRAX-330, Praxis Precision Medicines – Kiran Reddy MD
  • NBI-921352, Neurocrine Biosciences – Dietrich Haubenberger MHSc, MD, Medical Director, Early Clinical Development
  • Epidiolex for Tuberous Sclerosis, Greenwich Biosciences – Farhad Sahebkar MD, Senior Medical Director

Session X: Reformulated Drugs And Other Therapies – 3:20-4:30 P.M.

  • Buccal diazepam, Aquestive Therapeutics – Michael Rogawski MD, PhD, Consultant
  • Staccato alprazolam, Engage Therapeutics – Jouko Isojarvi MD, PhD, Chief Medical Officer
  • Novel intramuscular diazepam, Xeris Pharmaceuticals – Anh Nguyen MD, Director, Strategy Operations
  • CT-010, Cerebral Therapeutics – Dan Abrams MD, CEO
  • NRL-03, Neurelis – Craig Chambliss, CEO & Co-Founder
  • The Gut Brain Axis and Epilepsy, Bloom Science – Christopher Reyes PhD, Co-Founder & CEO
  • Ganaxolone IV, Marinus Pharmaceuticals – Julia Tsai PhD, Vice President of Clinical Development

Closing Remarks – 4:30-4:40 P.M.

  • Jacqueline French MD, Chief Medical and Innovation Officer, Epilepsy Foundation

Final Networking Reception – 4:40-5:30 P.M.

RSVP for Event / Log Back in

Additional menu options can be found in the menu bar on the left or at the top.